|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACAP2 |
Gene summary for ACAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACAP2 | Gene ID | 23527 |
| Gene name | ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 | |
| Gene Alias | CENTB2 | |
| Cytomap | 3q29 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q15057 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23527 | ACAP2 | HTA12-29-1 | Human | Pancreas | PDAC | 7.83e-32 | 6.74e-01 | 0.3722 |
| 23527 | ACAP2 | P1_S1_AK | Human | Skin | AK | 4.35e-05 | 3.55e-01 | -0.3399 |
| 23527 | ACAP2 | P2_S3_AK | Human | Skin | AK | 9.55e-05 | 3.69e-01 | -0.3287 |
| 23527 | ACAP2 | P4_S8_cSCC | Human | Skin | cSCC | 9.79e-13 | 3.14e-01 | -0.3095 |
| 23527 | ACAP2 | P5_S10_cSCC | Human | Skin | cSCC | 7.54e-13 | 3.64e-01 | -0.299 |
| 23527 | ACAP2 | P1_cSCC | Human | Skin | cSCC | 8.70e-07 | 4.98e-01 | 0.0292 |
| 23527 | ACAP2 | P2_cSCC | Human | Skin | cSCC | 2.84e-06 | 3.26e-01 | -0.024 |
| 23527 | ACAP2 | P4_cSCC | Human | Skin | cSCC | 1.20e-12 | 3.71e-01 | -0.00290000000000005 |
| 23527 | ACAP2 | P10_cSCC | Human | Skin | cSCC | 1.84e-09 | 4.44e-01 | 0.1017 |
| 23527 | ACAP2 | male-WTA | Human | Thyroid | PTC | 2.25e-23 | 7.61e-02 | 0.1037 |
| 23527 | ACAP2 | PTC01 | Human | Thyroid | PTC | 6.09e-20 | 1.63e-01 | 0.1899 |
| 23527 | ACAP2 | PTC03 | Human | Thyroid | PTC | 1.23e-06 | 3.46e-01 | 0.1784 |
| 23527 | ACAP2 | PTC04 | Human | Thyroid | PTC | 6.12e-29 | 5.43e-01 | 0.1927 |
| 23527 | ACAP2 | PTC05 | Human | Thyroid | PTC | 3.98e-17 | 6.47e-01 | 0.2065 |
| 23527 | ACAP2 | PTC06 | Human | Thyroid | PTC | 2.27e-30 | 7.39e-01 | 0.2057 |
| 23527 | ACAP2 | PTC07 | Human | Thyroid | PTC | 3.01e-33 | 5.89e-01 | 0.2044 |
| 23527 | ACAP2 | ATC09 | Human | Thyroid | ATC | 4.79e-14 | 2.03e-01 | 0.2871 |
| 23527 | ACAP2 | ATC11 | Human | Thyroid | ATC | 3.53e-08 | 5.81e-01 | 0.3386 |
| 23527 | ACAP2 | ATC12 | Human | Thyroid | ATC | 9.03e-20 | 4.47e-01 | 0.34 |
| 23527 | ACAP2 | ATC13 | Human | Thyroid | ATC | 8.68e-30 | 5.66e-01 | 0.34 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00988767 | Cervix | CC | vesicle-mediated transport to the plasma membrane | 34/2311 | 136/18723 | 3.75e-05 | 5.91e-04 | 34 |
| GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
| GO:19900909 | Cervix | CC | cellular response to nerve growth factor stimulus | 14/2311 | 53/18723 | 4.09e-03 | 2.54e-02 | 14 |
| GO:19900897 | Cervix | CC | response to nerve growth factor | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
| GO:199009012 | Cervix | N_HPV | cellular response to nerve growth factor stimulus | 6/534 | 53/18723 | 3.86e-03 | 3.05e-02 | 6 |
| GO:199008913 | Cervix | N_HPV | response to nerve growth factor | 6/534 | 56/18723 | 5.08e-03 | 3.73e-02 | 6 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0098876 | Colorectum | AD | vesicle-mediated transport to the plasma membrane | 57/3918 | 136/18723 | 2.30e-08 | 1.27e-06 | 57 |
| GO:1990090 | Colorectum | AD | cellular response to nerve growth factor stimulus | 26/3918 | 53/18723 | 4.87e-06 | 1.28e-04 | 26 |
| GO:1990089 | Colorectum | AD | response to nerve growth factor | 26/3918 | 56/18723 | 1.71e-05 | 3.59e-04 | 26 |
| GO:0032456 | Colorectum | AD | endocytic recycling | 28/3918 | 73/18723 | 4.87e-04 | 5.30e-03 | 28 |
| GO:00988762 | Colorectum | MSS | vesicle-mediated transport to the plasma membrane | 54/3467 | 136/18723 | 6.20e-09 | 3.95e-07 | 54 |
| GO:00161972 | Colorectum | MSS | endosomal transport | 79/3467 | 230/18723 | 7.04e-09 | 4.39e-07 | 79 |
| GO:19900902 | Colorectum | MSS | cellular response to nerve growth factor stimulus | 23/3467 | 53/18723 | 2.56e-05 | 5.31e-04 | 23 |
| GO:19900892 | Colorectum | MSS | response to nerve growth factor | 23/3467 | 56/18723 | 7.34e-05 | 1.23e-03 | 23 |
| GO:00324561 | Colorectum | MSS | endocytic recycling | 26/3467 | 73/18723 | 4.05e-04 | 4.99e-03 | 26 |
| GO:00988763 | Colorectum | FAP | vesicle-mediated transport to the plasma membrane | 42/2622 | 136/18723 | 3.16e-07 | 1.78e-05 | 42 |
| GO:00161973 | Colorectum | FAP | endosomal transport | 56/2622 | 230/18723 | 1.79e-05 | 4.53e-04 | 56 |
| GO:19900904 | Colorectum | FAP | cellular response to nerve growth factor stimulus | 17/2622 | 53/18723 | 6.20e-04 | 6.82e-03 | 17 |
| GO:19900893 | Colorectum | FAP | response to nerve growth factor | 17/2622 | 56/18723 | 1.24e-03 | 1.16e-02 | 17 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa041448 | Colorectum | CRC | Endocytosis | 65/1091 | 251/8465 | 1.27e-08 | 1.06e-06 | 7.19e-07 | 65 |
| hsa041449 | Colorectum | CRC | Endocytosis | 65/1091 | 251/8465 | 1.27e-08 | 1.06e-06 | 7.19e-07 | 65 |
| hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414414 | Lung | IAC | Endocytosis | 51/1053 | 251/8465 | 2.25e-04 | 2.54e-03 | 1.68e-03 | 51 |
| hsa0414415 | Lung | IAC | Endocytosis | 51/1053 | 251/8465 | 2.25e-04 | 2.54e-03 | 1.68e-03 | 51 |
| hsa0414423 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
| hsa0414433 | Lung | AIS | Endocytosis | 52/961 | 251/8465 | 9.74e-06 | 3.04e-04 | 1.95e-04 | 52 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0414442 | Oral cavity | EOLP | Endocytosis | 71/1218 | 251/8465 | 5.28e-09 | 8.97e-08 | 5.29e-08 | 71 |
| hsa0414452 | Oral cavity | EOLP | Endocytosis | 71/1218 | 251/8465 | 5.28e-09 | 8.97e-08 | 5.29e-08 | 71 |
| hsa0414461 | Oral cavity | NEOLP | Endocytosis | 62/1112 | 251/8465 | 3.56e-07 | 4.92e-06 | 3.09e-06 | 62 |
| hsa0414471 | Oral cavity | NEOLP | Endocytosis | 62/1112 | 251/8465 | 3.56e-07 | 4.92e-06 | 3.09e-06 | 62 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACAP2 | SNV | Missense_Mutation | novel | c.1611N>C | p.Lys537Asn | p.K537N | Q15057 | protein_coding | tolerated(0.29) | benign(0.031) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| ACAP2 | insertion | Frame_Shift_Ins | novel | c.1145_1146insTATATGTGTAT | p.Gly383IlefsTer4 | p.G383Ifs*4 | Q15057 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| ACAP2 | insertion | Frame_Shift_Ins | novel | c.1144_1145insTTATTAAACAGAAGATCTGTGC | p.Thr382IlefsTer16 | p.T382Ifs*16 | Q15057 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| ACAP2 | SNV | Missense_Mutation | c.1358N>G | p.Ser453Cys | p.S453C | Q15057 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| ACAP2 | SNV | Missense_Mutation | c.1172N>T | p.Ser391Phe | p.S391F | Q15057 | protein_coding | deleterious(0.02) | benign(0.187) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACAP2 | SNV | Missense_Mutation | novel | c.360N>G | p.Phe120Leu | p.F120L | Q15057 | protein_coding | tolerated(0.19) | benign(0.354) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACAP2 | SNV | Missense_Mutation | rs147239672 | c.2309N>A | p.Arg770His | p.R770H | Q15057 | protein_coding | deleterious(0) | possibly_damaging(0.77) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ACAP2 | SNV | Missense_Mutation | c.1295N>T | p.Thr432Ile | p.T432I | Q15057 | protein_coding | tolerated(0.12) | possibly_damaging(0.733) | TCGA-A6-6138-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ACAP2 | SNV | Missense_Mutation | c.382N>A | p.Glu128Lys | p.E128K | Q15057 | protein_coding | tolerated(0.14) | benign(0.107) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ACAP2 | SNV | Missense_Mutation | rs779591643 | c.1046N>A | p.Arg349His | p.R349H | Q15057 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |